Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 11/20 | 0.56 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.45 |
| ▸ | HPGDS | O60760 | 3/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2471410 | 0.97 | GABRA5 (0.53) | GABRA5RIPK2HPGDS | |
| SCHEMBL2471881 | 0.97 | GABRA5 (0.53) | GABRA5RIPK2HPGDS | |
| SCHEMBL2473240 | 0.92 | GABRA5 (0.53) | GABRA5RIPK2HPGDSMAPK8MAPK14 | |
| SCHEMBL2472225 | 0.90 | GABRA5 (0.51) | GABRA5RIPK2MAPK8MAPK14MAPT | |
| SCHEMBL2471420 | 0.89 | GABRA5 (0.50) | GABRA5RIPK2HPGDS | |
| SCHEMBL2471693 | 0.89 | GABRA5 (0.50) | GABRA5RIPK2HPGDSMAPTRAB9A | |
| SCHEMBL2472558 | 0.88 | GABRA5 (0.56) | GABRA5RIPK2 | |
| SCHEMBL2470562 | 0.88 | GABRA5 (0.59) | GABRA5 | |
| SCHEMBL2471743 | 0.87 | GABRA5 (0.49) | GABRA5RIPK2MAPTRAB9A | |
| SCHEMBL2469011 | 0.87 | GABRA5 (0.53) | GABRA5RIPK2MAPK8MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968973-B1 | ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-10-05 | — | — | EP | claimed |
| US-7414061-B2 | Aryl-isoxazol-4-yl-imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-08-19 | — | — | US | claimed |
| US-20070161654-A1 | Aryl-isoxazol-4-yl-imidazole derivatives | HOFFMANN-LA ROCHE INC. | 2007-07-12 | — | — | US | claimed |
| EP-1968973-B1 | ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-10-05 | — | — | EP | disclosed |
| US-7414061-B2 | Aryl-isoxazol-4-yl-imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20070161654-A1 | Aryl-isoxazol-4-yl-imidazole derivatives | HOFFMANN-LA ROCHE INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161654-A1 | Aryl-isoxazol-4-yl-imidazole derivatives | GABRA5, GABRA4, GABRA1 | GABRA5 1/4885RIPK2 3640/4885HPGDS 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.